



FOR IMMEDIATE RELEASE

[August 11, 2026]

Medicare Quality Measures Spotlight Medication Safety— IntractMD™ Identifies Hidden Supplement Risks

Patent-pending platform from Resolve Medical, LLC screens prescriptions, supplements and foods together to support safer medication reviews as Medicare expands quality measurement.

CLEVELAND, Ohio — [August 11, 2026] — Millions of older Americans take prescription medications together with vitamins, herbal supplements and over-the-counter products. Yet during Medicare Comprehensive Medication Reviews (CMRs), identifying those non-prescription products often depends on what patients can remember during a single conversation.

That gap is becoming more important.

Beginning with the 2027 Medicare Star Ratings, two new Part D quality measures place greater emphasis on medication safety in older adults, while Medicare has already nearly doubled the number of beneficiaries eligible for annual Comprehensive Medication Reviews. Together, those changes increase both the volume of reviews and the importance of identifying everything a patient is taking—not just prescription medications.

Resolve Medical, LLC today announced how its patent-pending IntractMD™ platform helps health plans, pharmacy benefit managers, health systems and pharmacy organizations identify interactions involving prescriptions, dietary supplements, vitamins and foods in a single workflow as described at: www.resolve.med

Why this matters now

Several Medicare changes are already affecting organizations today.

Effective January 1, 2025, the Centers for Medicare & Medicaid Services (CMS) expanded eligibility for Part D Medication Therapy Management (MTM), increasing the number of beneficiaries eligible for annual Comprehensive Medication Reviews from approximately 3.6 million to roughly 7.1 million.

At the same time, CMS is calculating performance for two Pharmacy Quality Alliance measures that become part of the 2027 Medicare Star Ratings:

- Concurrent Use of Opioids and Benzodiazepines
- Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults



Performance for those measures is based on 2025 measurement-year data, meaning organizations are already being evaluated.

Separately, the MTM Program Completion Rate for Comprehensive Medication Review moves temporarily to the CMS Display Page for the 2025 and 2026 measurement years before returning as a Star Ratings measure beginning with the 2029 ratings using 2027 performance data.

The challenge isn't prescription drugs—it's everything else

CMS defines a Comprehensive Medication Review as an annual review of a beneficiary's complete medication regimen, including prescription medications, over-the-counter medications, herbal products and dietary supplements.

Prescription medications are typically available through pharmacy claims and electronic health records. Supplements, vitamins and many over-the-counter products are not.

As a result, pharmacists frequently rely on patient recall to identify products that may meaningfully affect medication safety.

That becomes increasingly important when evaluating cumulative medication burden. For example, commonly purchased over-the-counter allergy medications may contribute to anticholinergic burden even though they may never appear in a prescription record. [“The missing piece is supplements.”](#)

“Every health plan and health system we speak with already has prescription drug interaction checking,” said Tom Lash, Founder of Resolve Medical.

“What they don't have is a practical way to consistently capture the supplement layer. If pharmacists don't know a patient is taking supplements or certain over-the-counter products, or don't have an immediate prompt while reviewing the patient's medication regimen, they can't fully evaluate medication risk. We didn't just build a SaaS subscription to a database. We built a broader four-surface platform that fits the existing pharmacy workflow — and it looks different depending on whether you are the pharmacist in the encounter, the case manager working a panel, or the plan looking at a population.”

What IntractMD does

IntractMD screens prescription medications together with dietary supplements, vitamins and foods in a single query, prioritizing clinically actionable risks while producing a Composite Polypharmacy Risk Score (CPRS) across eight clinical dimensions, including bleeding risk, cardiac risk, central nervous system effects, CYP450 interactions and renal/hepatic considerations.

The platform draws on a precomputed knowledge base containing more than 173,000 drug-pair analyses covering approximately 590 commonly prescribed U.S. medications. Drug terminology is standardized using RxNorm, and interaction content is grounded in FDA-approved prescribing information. Results are available in both English and Spanish and can be shared directly with patients following a medication review.



Resolve Medical delivers IntractMD across four connected applications designed for different users within the medication management workflow:

- A patient-facing interaction checker for use before or after appointments.
- A proactive population-screening engine for health plans and pharmacy organizations.
- A clinical workflow application for MTM pharmacists and case managers.
- A deprescribing review application, currently in pilot preview, that identifies medications appearing in published deprescribing criteria while linking users to the original clinical sources.

The patient-facing IntractMD application is publicly available at: www.intractMD.com

Institutional applications are currently available through pilot programs. Learn more at: www.resolve.med

IntractMD is an analytics and clinical decision-support information platform. It does not complete Comprehensive Medication Reviews, determine CMS measure performance or establish payment eligibility. Clinical decisions remain the responsibility of licensed healthcare professionals.

No-cost pilot program now available

Resolve Medical is offering qualified health plans, pharmacy benefit managers, health systems and pharmacy organizations a no-cost, 60-day pilot. Pilots operate on Resolve Medical's cloud infrastructure and require no software installation or IT integration to begin.

About Resolve Medical, LLC

Resolve Medical, LLC is a Cleveland-based healthcare technology company focused on medication safety and polypharmacy risk reduction. Its patent-pending IntractMD™ platform helps patients and healthcare organizations identify clinically significant interactions involving prescription medications, supplements, vitamins and foods through four integrated workflow applications.

More information is available at www.resolve.med and www.intractmd.com.

Media Contact

Tom Lash, Founder

Resolve Medical, LLC

216-509-0672

info@resolve.med